Home › Funds › SABBY MANAGEMENT, LLC › BCTXL

SABBY MANAGEMENT, LLC position in BCTXL

BRIACELL THERAPEUTICS CORP · Health Care

SABBY MANAGEMENT, LLC reported holding 136,365 shares of BCTXL (BRIACELL THERAPEUTICS CORP) in its Q3 2026 13F filing — a position valued at US$158K, representing 3.52% of its reported portfolio and ranking #11 among its reported holdings. SABBY MANAGEMENT, LLC has disclosed BCTXL holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)136.37K sh
Reported value held$158.18K
Portfolio Weight3.52%
First reportedQ1 2026
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SABBY MANAGEMENT, LLC's BCTXL position evolved

SABBY MANAGEMENT, LLC first disclosed a stake in BCTXL in Q1 2026 at 380,686 shares (US$392K). Across 3 filings, SABBY MANAGEMENT, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 136,365 shares valued at US$158K — a reduction of -54,018 shares quarter over quarter.. Notable position changes include a 50% trim in Q2 2026, a 28% trim in Q3 2026.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 380.69K $392.14K New
Q2 2026 190.38K $169.44K Reduce
Q3 2026 136.37K $158.18K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCTXL and 13F data

BCTXL (BRIACELL THERAPEUTICS CORP) is a Health Care company. 10 other funds we track also report a position in BCTXL — the largest reported positions include Empery Asset Management, LP (US$267K), IRIDIAN ASSET MANAGEMENT LLC/CT (US$75K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCTXL

All BCTXL fund holders →

FAQ

How long has SABBY MANAGEMENT, LLC held BCTXL?

SABBY MANAGEMENT, LLC has disclosed BCTXL holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is SABBY MANAGEMENT, LLC's current position in BCTXL?

As of Q3 2026, SABBY MANAGEMENT, LLC holds 136.37K shares of BCTXL (BRIACELL THERAPEUTICS CORP), valued at $158.18K, representing 3.52% of its reported portfolio and ranking #11.

Has SABBY MANAGEMENT, LLC been buying or selling BCTXL?

In the latest 13F filing (Q3 2026), SABBY MANAGEMENT, LLC reduced its position in BCTXL.

Which other funds hold BCTXL?

Other major institutional holders of BCTXL include Empery Asset Management, LP, IRIDIAN ASSET MANAGEMENT LLC/CT, among 10 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.